A recent Obstetrics & Gynaecology digest,
as sent to subscribers

Study Type: Cross-sectional pooled analysis of three population-based case-control studies

Key Question: Do known and putative endometriosis risk factors and comorbidities differ by surgically-visualised lesion macrophenotype (superficial peritoneal, endometrioma, deep, or combined)?

Key Findings:

• Among 1,244 cases: 71% SPE only, 8% endometrioma, 11% deep, 10% combined deep+endometrioma.
• Earlier menarche (≤11 vs 12 years) increased odds of SPE-only (OR 1.29, 95% CI 1.01–1.65) and deep+endometrioma (OR 2.07, CI 1.11–3.86), but not endometrioma or deep lesions alone (p-het=0.05).
• Chronic overlapping pain conditions increased odds of SPE-only (OR 1.80/condition) and deep lesions (OR 1.76/condition), but not endometrioma-containing phenotypes (p-het=0.0001).

Clinical Relevance: Supports a shift towards macrophenotype-stratified risk assessment and biomarker research in endometriosis, relevant to UK diagnostic pathways and personalised management strategies under NHS gynaecology services.

Limitations: Cross-sectional design precludes causal inference regarding risk factor-lesion phenotype relationships.

Study Type: Large prospective cohort study (Norwegian MoBa cohort)

Key Question: In term-born children, does gestational age (37–41 weeks) or fetal size (SGA/AGA/LGA) show a more lasting association with neurodevelopment from infancy to adolescence?

Key Findings:

• Earlier term birth was linked to poorer early language/motor development, but this effect faded by 18 months and was negligible by age 5.
• SGA status showed persistent adverse associations with academic performance into adolescence, including lower maths scores at ages 10–11 (β=-2.32, 95% CI -3.15 to -1.49), 13–14 (β=-1.79), and 14–15 (β=-1.85).
• Gestational age and fetal size effects were statistically independent of one another.

Clinical Relevance: For UK clinicians counselling on timing of term delivery, fetal growth status—not gestational age alone—appears to carry the more durable neurodevelopmental risk signal, informing individualised antenatal surveillance and birth-timing discussions.

Limitations: Observational design precludes causal inference, and residual confounding (e.g., unmeasured placental or socioeconomic factors) may explain part of the SGA association.

Study Type: Retrospective observational cohort study (pre/post implementation comparison)

Key Question: Does universal dispensation of low-dose aspirin to all patients presenting for prenatal care by 16 weeks reduce preeclampsia with severe features, compared with risk-factor-based prescribing?

Key Findings:

• Preeclampsia with severe features fell from 6.9% to 5.1% after universal aspirin dispensation (aOR 0.65, 95% CI 0.60–0.72), with later onset of diagnosis in the aspirin epoch.
• Benefit extended to patients with chronic hypertension (aOR 0.72, 95% CI 0.59–0.86).
• No increase in abruption, postpartum haemorrhage, or neonatal complications; 80.4% of eligible patients received aspirin via direct dispensation.

Clinical Relevance: Supports considering simplified, universal aspirin prophylaxis (rather than complex risk-stratified screening) in high-prevalence populations, with direct dispensation potentially improving adherence—relevant to NHS efforts to streamline preeclampsia prevention pathways and address health inequalities in high-risk maternity populations.

Limitations: Pre/post observational design cannot exclude secular trends or confounding from concurrent changes in care over the 5-year study period.

Study Type: Retrospective cross-sectional imaging study (MRI-based anatomical analysis)

Key Question: Does clitoral-vestibular bulb anatomy change with age in women without pelvic floor dysfunction?

Key Findings:

• Older Adult women (≥50y) had shorter clitoral body length than Early Midlife women (24.1mm vs 27.9mm; P=.006), and more caudal positioning of the clitoral-vestibular complex versus both younger groups (P<.001).
• Increasing age weakly correlated with smaller vestibular bulb volume (ρ=-0.20; P=.02) and shorter clitoral length (ρ=-0.21; P=.01), and moderately with caudal displacement (ρ=-0.43; P<.001); clitoral volume was unchanged (ρ=-0.03; P=.73).
• Shape analysis showed vestibular bulbs became more medially positioned and proportionally smaller relative to the clitoris with age (both ρ=-0.28; P=.001), while the clitoris itself was relatively spared.

Clinical Relevance: Provides normative anatomical data suggesting age-related atrophy and descent of the vestibular bulbs (not the clitoris) may underlie postmenopausal sexual dysfunction, informing counselling and future targeted interventions in UK menopause and sexual health services.

Limitations: Retrospective single-timepoint design cannot establish causality or distinguish menopause-driven changes from chronological ageing per se.

Study Type: Special Report / expert consensus commentary (not original research)

Key Question: Should PCOS be renamed to PMOS, and what are the practical implications of this reframing for obstetric and gynaecologic care?

Key Findings:

• PCOS has been renamed polyendocrine metabolic ovarian syndrome (PMOS) via international multistep consensus endorsed by 56 organisations, correcting the misleading "cyst" terminology (arrested antral follicles, not pathological cysts).
• PMOS affects 10–13% of reproductive-age women and is associated with miscarriage, gestational diabetes, hypertensive disorders, caesarean delivery, preterm birth, fetal growth restriction, and small-for-gestational-age infants, with many associations persisting after adjusting for age and BMI.
• Diagnostic criteria are unchanged (Rotterdam-type criteria: 2 of 3—ovulatory dysfunction, hyperandrogenism, elevated AMH/polyfollicular ovaries); the change is conceptual, emphasising lifelong endocrine-metabolic risk rather than ovarian/fertility focus alone.

Clinical Relevance: UK O&G clinicians should recognise PMOS as an obstetric risk modifier requiring documentation at booking and integration into antenatal risk pathways, alongside consistent psychological and cardiometabolic screening across the reproductive lifespan.

Limitations: As a consensus/opinion report rather than primary data, conclusions rely on synthesis of existing literature without new empirical analysis.

Study Type: Retrospective cohort study

Key Question: Does adding estimated fetal weight (EFW) growth velocity to standard biometric/Doppler criteria improve prediction of adverse perinatal outcomes in term small-for-gestational-age (SGA) fetuses?

Key Findings:

• Slow growth velocity (31.8% of cases) was associated with more frequent EFW <3rd centile (52.4% vs 23.2%, p<0.001) and abnormal umbilical artery Doppler (4.2% vs 1.0%, p=0.023), but not with higher composite adverse outcome (CAO) rates (22.7% vs 26.6%, p=0.689).
• Independent predictors of CAO were EFW <3rd centile, abnormal uterine artery PI, and low cerebroplacental ratio.
• Adding slow growth velocity did not improve predictive performance (AUC 0.64 vs 0.64, p=0.54).

Clinical Relevance: For UK units following growth surveillance pathways (e.g., SGA/FGR guidelines aligned with GAP/PIGF-based protocols), this suggests serial growth velocity assessment offers no incremental benefit over existing biometric and Doppler thresholds, supporting continued reliance on established criteria without added complexity.

Limitations: Single-centre retrospective design with modest CAO event numbers limits generalisability and power to detect smaller predictive gains.

Study Type: RCT (multicentre, double-blind, placebo-controlled)

Key Question: Does perioperative vaginal oestrogen therapy improve outcomes in postmenopausal women undergoing native-tissue prolapse surgery?

Key Findings:

• At 12 months, more women reported subjective improvement (PGI-I) with oestrogen vs placebo: 92% vs 80% (p=0.02).
• Pelvic floor-related quality of life was better with oestrogen (PFDI-20 median 17 vs 25, p=0.03); fewer reported pain/discomfort (EQ-5D-5L: 61% vs 77%, p=0.04).
• No differences in anatomical success, composite surgical success, sexual function, or reintervention rates.

Clinical Relevance: Supports offering adjunctive perioperative vaginal oestrogen as a low-risk, well-tolerated intervention to improve patient-reported outcomes after prolapse surgery within NHS shared decision-making pathways, without evidence of anatomical benefit.

Limitations: Notable dropout (57/293, ~19%) may affect precision of secondary outcome estimates and generalisability.

Study Type: Systematic review and meta-analysis (observational studies)

Key Question: Does the presence of cytoplasmic strings (CS) in human blastocysts predict improved IVF outcomes, particularly livebirth rate?

Key Findings:

• CS-positive blastocysts had significantly higher livebirth rate (OR 1.88, 95% CI 1.35–2.61) and clinical pregnancy rate (OR 2.20, 95% CI 1.29–3.75) versus CS-negative blastocysts.
• Higher CS quantity (≥5 vs 1–4) further increased odds of livebirth (OR 3.01, 95% CI 2.22–4.08); earlier CS onset/disappearance and faster progression to full blastocyst correlated with better outcomes.
• CS presence associated with better morphological grading (OR 2.40, 95% CI 1.17–4.92); overall evidence certainty was GRADE "very low" due to heterogeneity and risk of bias.

Clinical Relevance: CS assessment during time-lapse embryo monitoring could become a low-cost, non-invasive adjunct to improve embryo selection and IVF success rates within NHS/HFEA-regulated fertility services.

Limitations: Findings derive from heterogeneous observational studies with high bias risk, limiting confidence for immediate clinical adoption.